CliffBio
small molecule

BIVALIRUDIN

BIVALIRUDIN

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBIVALIRUDIN
Active ingredientBIVALIRUDIN
Strength250MG/VIAL
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2017
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.